Canopy's Purchase Of Mettrum Would Create Canadian Marijuana Giant

Posted: Updated:
Print

SMITHS FALLS, Ont. — Marijuana producer Canopy Growth Corp. is offering to buy Mettrum Health Corp. in a friendly all-stock deal valued at $430 million.

According to a report at the Financial Post, the new combined company would have 39,730 medical marijuana customers, or nearly half of the total customer base.

tweed marijuana
Operations at the Tweed Inc. facility in Smith Falls, Ont., on Nov. 11, 2015. Tweed is a subsidiary of Canopy Growth, which is aiming to merge with Mettrum. (Photo: James MacDonald/Bloomberg via Getty Images)

Construction and marijuana companies are poised to benefit from the Liberal Party's decisive win in Canada's election, with leader Justin Trudeau vowing to fund infrastructure spending with deficits and legalize cannabis.

Mettrum shareholders will be entitled to receive 0.7132 of a common share of Canopy under the offer, which would create a company with six facilities licensed to produce medical marijuana products.

Canopy's offer values Mettrum shares at $8.42 — $2.50 above the closing stock price Wednesday.

Assuming the deal gets shareholder approvals at both companies, Mettrum will become a wholly owned subsidiary of Canopy and Mettrum shareholders will own about 22.3 per cent of the combined company.

Mettrum's board has agreed to pay Canopy a $10-million termination fee under certain circumstances if the deal doesn't go through. Canopy will also have the right to match a superior proposal from a rival buyer.

tweed marijuana inc
Operations at Canopy Growth's Tweed subsidiary, Smiths Falls, Ont. (Photo: James MacDonald/Bloomberg via Getty Images

Canopy has grown into Canada's largest publicly traded cannabis company since the federal government revised the rules for producing and distributing marijuana for medical purposes. It's also is poised to sell so-called "lifestyle'' or "recreational'' pot if Ottawa moves to a legalize marijuana for non-medical use.

"Mettrum has established a line of cannabis products that work well in a medical context and will transition naturally into a natural and healthy lifestyle market,'' Canopy chairman and CEO Bruce Linton said in a statement Thursday.

The deal for Mettrum is Canopy's second acquisition this week.

On Monday, Canopy announced a deal to buy pharmaceutical distributor MedCann, which has placed the Canadian marijuana company's Tweed-branded cannabis strains in German pharmacies.

In a separate announcement, Mettrum said it plans to voluntarily add a small number of product lots to a voluntary recall announced on Nov. 1. It says some of the products were exposed to a plant spray with an undisclosed ingredient — a natural pesticide that Mettrum says has no impact on human health.

— With a file from The Huffington Post Canada

Also on HuffPost:

Close
Medical Marijuana Users Share Secrets
of
Share
Tweet
Advertisement
Share this
close
Current Slide

Suggest a correction